Trials / Completed
CompletedNCT02122809
Phase I Study of Chiauranib in Patients With Advanced Solid Tumors
Phase I Safety and Pharmacokinetics Study of Chiauranib in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Chipscreen Biosciences, Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chiauranib administered orally over a range of doses in patients with advanced solid tumors.
Detailed description
The purpose of this study is to assess the tolerability and safety include adverse events, vital signs, laboratory tests ,etc., of a range of doses of Chiauranib in solid tumor patients, and to determine the dose limit toxicity and the maximum tolerable dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chiauranib | Take orally |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2016-04-01
- Completion
- 2016-06-01
- First posted
- 2014-04-25
- Last updated
- 2016-06-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02122809. Inclusion in this directory is not an endorsement.